Menu Search
Equities

BioMaxima SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BMX:WSE

BioMaxima SA

Actions
Health CareMedical Equipment and Services
  • Price (PLN)12.05
  • Today's Change0.00 / 0.00%
  • Shares traded134.00
  • 1 Year change-11.07%
  • Beta0.3256
Data delayed at least 15 minutes, as of Mar 05 2026.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year BioMaxima SA had net income fall -8.70% from 586.00k to 535.00k despite revenues that grew 12.96% from 47.69m to 53.88m over the same period.
Gross margin48.69%
Net profit margin1.07%
Operating margin2.40%
Return on assets0.85%
Return on equity1.39%
Return on investment1.11%
More ▼

Cash flow in PLNView more

In 2024, cash reserves at BioMaxima SA fell by 594.00k. Cash Flow from Financing totalled 317.00k or 0.59% of revenues. In addition the company used 152.00k for operations while cash used for investing totalled 759.00k.
Cash flow per share1.02
Price/Cash flow per share11.78
Book value per share11.16
Tangible book value per share11.02
More ▼

Balance sheet in PLNView more

BioMaxima SA has a Debt to Total Capital ratio of 25.44%, a higher figure than the previous year's 13.19%.
Current ratio1.41
Quick ratio0.7106
Total debt/total equity0.3411
Total debt/total capital0.2544
More ▼

Growth rates in PLN

Year on year, growth in earnings per share excluding extraordinary items dropped -5.98%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		291.46
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.